News|Podcasts|November 19, 2026

Podcast: NIH Team Details Path From Ketamine Metabolite Discovery to Phase 2 Trials

Listen
0:00 / 0:00

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.

In this episode of “Psychopharm Today,” host Jenessa Johnston, PhD, and guests Carlos Zarate, MD; Todd Gould, MD; and Craig J. Thomas, PhD, described the development of 2R,6R-hydroxynorketamine (2R,6R-HNK) for depression and pain.

The program began with a mismatch. Across replicated clinical studies, a single ketamine infusion produced antidepressant effects within hours that persisted 1 to 2 weeks—far longer than ketamine’s few-hour half-life would predict. Metabolite analyses identified hydroxynorketamines detectable for 3 to 7 days in some participants, tracking the onset-offset curve of the clinical response and suggesting ketamine might act as a prodrug.

Testing that hypothesis required isolating individual metabolites, since ketamine generates roughly 2 dozen within minutes in rodents and humans. At the National Center for Advancing Translational Sciences, chemists synthesized the approximately 20 naturally occurring metabolites, characterizing 5 to 10 in usable quantity. 2R,6R-HNK—one of 12 hydroxynorketamines formed from ketamine—stood out: active across preclinical assays, free of sedative or dissociative effects, and with favorable pharmacokinetics.

Two experiments were pivotal. A ketamine analog engineered to resist metabolism to 6-hydroxynorketamines showed diminished antidepressant-like activity, indicating the biotransformation is necessary for ketamine’s full effect. And 2R,6R-HNK alone reproduced ketamine’s rodent profile—rapid onset with effects sustained days after the drug cleared.

Critically, 2R,6R-HNK is not a potent NMDA receptor antagonist. Animal models showed no dissociation, dizziness, or abuse-potential signals, findings the investigators said have held in a completed phase 1 study. The underlying mechanism remains unidentified, as does whether the antidepressant and analgesic effects converge on a single target.

NIH and the University of Maryland developed the compound in-house rather than partnering with industry, which the investigators said let scientific questions rather than commercial ones steer the program. Four phase 2 trials are now underway, beginning with treatment-resistant depression, with interest in pain, obsessive-compulsive disorder, anhedonia, and bipolar depression. Because the prodrug hypothesis implies shared pharmacology, ketamine nonresponders would not be expected to respond—though better tolerability may allow earlier intervention.

Dr Johnston is a postdoctoral fellow at National Institute of Mental Health.

Dr Zarate is the chief of the Section on the Neurobiology and Treatment of Mood Disorders, and chief of Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health. He is also a clinical professor of Psychiatry and Behavioral Sciences at The George Washington University.

Dr Thomas is a senior scientist at Precision Therapeutics & Translational Technologies.

Dr Gould is a neuropharmacologist and professor in the department of psychiatry at the University of Maryland Baltimore School of Medicine.


Related to this article